APRE

Aprea Therapeutics, Inc.

0.6403

+0.0003+0.04%

After Hours: 0.6206 -0.0197 -3.08%19:11 08/21 EDT

Daily

Weekly

Monthly

Quarterly

Yearly

OPEN/PREV CLOSE0.8150/0.8052

TODAY RANGE0.8025-0.9900

VOL2.12M

MARKET CAP11.96M

52 WEEK RANGE0.5480-1.690

AVG VOL (3M)152.12K

% TURNOVER16.48%

TURNOVER--

P/E (TTM)-0.8826

% RANGE23.29%

EPS(TTM)-1.0763

P/E(FORWARD)-3.0891

P/B0.3003

BVPS3.163

DIVIDEND--

P/S27.22

BETA--

DIV YIELD0.00%

FREE FLOAT MKT CAP9.51M

SHARES OUTSTANDING12.59M

NEXT EARNINGS11/10-11/16

FREE FLOAT10.01M

LOT SIZE1

EX-DATE02/13/2023

News

Press Releases

Financial Reports

Profile

TipRanks·08/14 14:10
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), Nektar Therapeutics (NKTR) and Aprea Therapeutics (APRE)
Dow Jones·08/13 13:06
Aprea Therapeutics Is Maintained at Outperform by Wedbush
Dow Jones·08/13 13:06
Aprea Therapeutics Price Target Cut to $3.00/Share From $6.00 by Wedbush
TipRanks·08/13 11:50
Analysts Offer Insights on Healthcare Companies: Kailera Therapeutics, Inc. (KLRA), Warby Parker (WRBY) and Aprea Therapeutics (APRE)
NASDAQ·08/12 17:15
Aprea Advances APR-1051; Phase 1 Enrollment Accelerates
TipRanks·08/12 12:58
Aprea Therapeutics advances APR-1051 oncology pipeline progress
Seeking Alpha·08/12 12:32
Aprea Therapeutics GAAP EPS of -$0.07 beats by $0.16
Dow Jones·08/12 12:30
Press Release: Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Dow Jones·08/12 12:30
Press Release: Aprea Therapeutics Announces -2-
TipRanks·08/10 16:25
Aprea Therapeutics: Buy Rating Reiterated as APR-1051 Clinical Momentum Builds; $1.20 Price Target Maintained
TipRanks·08/04 16:30
Aprea’s ATRN-119 Trial Completion: What It Means For APRE Investors
Seeking Alpha·07/01 14:20
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in June 2026
TipRanks·06/17 21:01
Aprea Shareholders Approve Directors, Reverse Split Flexibility
TipRanks·06/15 12:40
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV) and Aprea Therapeutics (APRE)
TipRanks·06/01 15:55
Pantginis Reiterates Buy on APR-1051 Developer, Keeps $1.20 Price Target After Encouraging ASCO Data and Superior Safety Profile

Same Industry

Name/Symbol

Change%

Price

Aprea Therapeutics, Inc.

APRE

+0.04%

0.6403

REGN

GRDX

BIONTECH

BNTX

+5.12%

116.57

United Therapeutics Corp.

UTHR

-1.51%

513.12

Siga Technologie

SIGA

+2.36%

3.040

Vertex Pharmaceuticals Inc

VRTX

+1.44%

548.05

Moderna

MRNA

+8.86%

145.13

Charles Riv Labs Intl Inc

CRL

+1.28%

295.19

Medpace Holdings

MEDP

-0.12%

620.03

Talphera Inc

TLPH

0.00%

1.190

ICON plc

ICLR

-1.17%

172.23

CBPO

Iqvia Hldgs Inc

IQV

+1.47%

259.82

MOLECULAR PARTNERS AG

MOLN

+4.02%

4.400

Arcturus Therape

ARCT

+22.38%

13.45

PRAH

Gilead Sciences Inc

GILD

+1.87%

146.12

Incyte Corp

INCY

+0.46%

127.81

Aptevo Therapeutics Inc

APVO

-10.07%

2.410

BSTC

No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.